Ra Pharmaceuticals Inc (RARX) - Financial and Strategic SWOT Analysis Review

  • ID: 4391490
  • SWOT Analysis
  • 44 pages
  • GlobalData
1 of 5
Ra Pharmaceuticals Inc (RARX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Ra Pharmaceuticals Inc (Ra Pharmaceuticals) is a clinical stage biopharmaceutical company that develops therapeutics for the treatment of diseases caused due to uncontrolled activation of the complement system. Ra Pharmaceuticals develops its pipeline products through its proprietary peptide chemistry platform. Its lead product candidate, RA101495 is a self-administered subcutaneous (SC) injection into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Ra Pharmaceuticals pipeline also includes RA101495, an administered SC, to treat debilitating complement-mediated diseases such as atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG) and lupus nephritis (LN). The company also carries out various preclinical programs intended for the treatment of orphan renal diseases, ocular, autoimmune and CNS diseases; and a non-complement cardiovascular product candidate. Ra Pharmaceuticals is headquartered on Cambridge, Massachusetts, the US.

Ra Pharmaceuticals Inc Key Recent Developments

May 09, 2018: Ra Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
Apr 18, 2018: Ra Pharmaceuticals Names John C. King as Chief Commercial Officer
Mar 14, 2018: Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
Nov 09, 2017: Ra Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update
Aug 09, 2017: Ra Pharmaceuticals Reports Second Quarter 2017 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5
Section 1 - About the Company
  • Ra Pharmaceuticals Inc - Key Facts
  • Ra Pharmaceuticals Inc - Key Employees
  • Ra Pharmaceuticals Inc - Key Employee Biographies
  • Ra Pharmaceuticals Inc - Major Products and Services
  • Ra Pharmaceuticals Inc - History
  • Ra Pharmaceuticals Inc - Company Statement
  • Ra Pharmaceuticals Inc - Locations And Subsidiaries
  • Head Office
Section 2 - Company Analysis
  • Ra Pharmaceuticals Inc - Business Description
  • Ra Pharmaceuticals Inc - Corporate Strategy
  • Ra Pharmaceuticals Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Ra Pharmaceuticals Inc - Strengths
  • Ra Pharmaceuticals Inc - Weaknesses
  • Ra Pharmaceuticals Inc - Opportunities
  • Ra Pharmaceuticals Inc - Threats
  • Ra Pharmaceuticals Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Ra Pharmaceuticals Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 09, 2018: Ra Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
  • Mar 14, 2018: Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
  • Nov 09, 2017: Ra Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update
  • Aug 09, 2017: Ra Pharmaceuticals Reports Second Quarter 2017 Financial Results
  • Jul 18, 2017: OMRF researcher tests new approach for treating deadly blood infection
  • May 11, 2017: Ra Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
  • Mar 06, 2017: Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • Ra Pharmaceuticals Inc, Key Facts
  • Ra Pharmaceuticals Inc, Key Employees
  • Ra Pharmaceuticals Inc, Key Employee Biographies
  • Ra Pharmaceuticals Inc, Major Products and Services
  • Ra Pharmaceuticals Inc, History
  • Ra Pharmaceuticals Inc, Key Competitors
  • Ra Pharmaceuticals Inc, Ratios based on current share price
  • Ra Pharmaceuticals Inc, Annual Ratios
  • Ra Pharmaceuticals Inc, Annual Ratios
  • Ra Pharmaceuticals Inc, Interim Ratios
  • Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Ra Pharmaceuticals Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Ra Pharmaceuticals Inc, Performance Chart (2014 - 2017)
  • Ra Pharmaceuticals Inc, Ratio Charts
  • Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Bioverativ Inc
  • Apellis Pharmaceuticals Inc
  • Amyndas Pharmaceuticals LLC
  • Alnylam Pharmaceuticals Inc
  • Alexion Pharmaceuticals Inc
  • Achillion Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll